BCG overexpressing an endogenous STING agonist provides enhanced protection against pulmonary tuberculosis.
STING is a key cytosolic receptor for small nucleotides and plays a key role in anti-cancer and antiviral immunity. Cyclic dinucleotide STING agonists may comprise a novel class of vaccine adjuvants capable of inducing cellular immune responses and protective efficacy against intracellular pathogens. We generated a recombinant BCG (BCG-disA-OE) that overexpresses the endogenous mycobacterial diadenylate cyclase gene and releases high levels of the STING agonist c-di-AMP. We used a 24-week guinea pig vaccination-M.tb. challenge model to test the protective efficacy of BCG-disA-OE versus wild-type BCG and measured lung weights, pathology scores, and M.tb. organ CFU counts. BCG-disA-OE elicited statistically significantly stronger TNF-α, IL-6, IL-1β, IRF3, and IFN-β levels than BCG-WT in vitro in murine macrophages. In vivo in guinea pigs we found that BCG-disA-OE reduced lung weights, pathology scores, and M.tb. CFU counts in lungs by 28% (p<0.05), 34%, and 2.0 log10 CFU units (p < 0.5) compared with BCG-WT, respectively. We report a strategy of delivering a STING agonist from within live BCG. Overproduction of the STING agonist c-di-AMP significantly enhanced the protective efficacy of BCG against pulmonary and extrapulmonary tuberculosis. Our findings support the development of BCG-vectored STING agonists as a TB vaccine strategy.